| Metabolomic fingerprinting: challenges and opportunities AK Kosmides, K Kamisoglu, SE Calvano, SA Corbett, I Androulakis Critical Reviews™ in Biomedical Engineering 41 (3), 2013 | 178 | 2013 |
| Polymer‐based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis DR Lewis, K Kamisoglu, AW York, PV Moghe Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3 (4 …, 2011 | 96 | 2011 |
| Human metabolic response to systemic inflammation: assessment of the concordance between experimental endotoxemia and clinical cases of sepsis/SIRS K Kamisoglu, B Haimovich, SE Calvano, SM Coyle, SA Corbett, ... Critical Care 19, 1-10, 2015 | 84 | 2015 |
| Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial T Dam, AL Boxer, LI Golbe, GU Höglinger, HR Morris, I Litvan, AE Lang, ... Nature medicine 27 (8), 1451-1457, 2021 | 81 | 2021 |
| Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges J Sunderram, S Sofou, K Kamisoglu, V Karantza, IP Androulakis Journal of translational medicine 12, 1-9, 2014 | 67 | 2014 |
| Preparation and characterization of antibacterial zeolite–polyurethane composites K Kamýþoðlu, EA Aksoy, B Akata, N Hasirci, N Baç Journal of applied polymer science 110 (5), 2854-2861, 2008 | 65 | 2008 |
| Branched‐chain amino acid supplementation: impact on signaling and relevance to critical illness JSA Mattick, K Kamisoglu, MG Ierapetritou, IP Androulakis, F Berthiaume Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013 | 63 | 2013 |
| Temporal metabolic profiling of plasma during endotoxemia in humans K Kamisoglu, KE Sleight, SE Calvano, SM Coyle, SA Corbett, ... Shock 40 (6), 519-526, 2013 | 40 | 2013 |
| Tandem analysis of transcriptome and proteome changes after a single dose of corticosteroid: a systems approach to liver function in pharmacogenomics K Kamisoglu, S Sukumaran, E Nouri-Nigjeh, C Tu, J Li, X Shen, X Duan, ... Omics: a journal of integrative biology 19 (2), 80-91, 2015 | 20 | 2015 |
| Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels K Kamisoglu, A Acevedo, RR Almon, S Coyle, S Corbett, DC Dubois, ... Frontiers in pharmacology 8, 91, 2017 | 17 | 2017 |
| Integrated transcriptional and metabolic profiling in human endotoxemia K Kamisoglu, SE Calvano, SM Coyle, SA Corbett, IP Androulakis Shock 42 (6), 499-508, 2014 | 14 | 2014 |
| Topology and Dynamics of Signaling Networks: In Search of Transcriptional Control of the Inflammatory Response IP Androulakis, K Kubra, JS Mattick Annual Review of Biomedical Engineering 15 (1), 2013 | 14 | 2013 |
| Effects of coupled dose and rhythm manipulation of plasma cortisol levels on leukocyte transcriptional response to endotoxin challenge in humans K Kamisoglu, K Sleight, TT Nguyen, SE Calvano, SM Coyle, SA Corbett, ... Innate Immunity 20 (7), 774-784, 2014 | 11 | 2014 |
| Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic/pharmacodynamic model K Kamisoglu, A Phipps, C Jamois, V Buchheit, G Meneses-Lorente, ... Blood 130, 1267, 2017 | 9 | 2017 |
| Mechanistic modeling of inflammation JD Scheff, K Kamisoglu, IP Androulakis Systems pharmacology and pharmacodynamics, 325-352, 2016 | 5 | 2016 |
| P4‐038: PHARMACOKINETIC AND TARGET ENGAGEMENT (TE) ANALYSIS OF ANTI‐TAU ANTIBODY BIIB092 IN CYNOMOLGUS MONKEYS CNS FLUID COMPARTMENTS J Czerkowicz, TY Liu, W Chen, K Kamisoglu, W Wang, KK Muralidharan, ... Alzheimer's & Dementia 15, P1288-P1289, 2019 | 1 | 2019 |
| Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial T Dam, AL Boxer, LI Golbe, GU Höglinger, HR Morris, I Litvan, AE Lang, ... Nature Medicine 29 (11), 2955-2956, 2023 | | 2023 |
| Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021 … T Dam, AL Boxer, LI Golbe, GU Hoglinger, HR Morris, I Litvan, AE Lang, ... NATURE MEDICINE, 2022 | | 2022 |
| Allometric Scaling of Time-dependent CSF Exposure for Monoclonal Antibody-based Drugs between Cynomolgus Macaques and Humans D MacCannell, I Nestorov, KK Muralidharan, M Monine, K Kamisoglu JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S24-S25, 2018 | | 2018 |
| Population PK/PD Model of an Extracellular Tau Targeting mAb Being Developed for the Treatment of Progressive Supranuclear Palsy (PSP) and Alzheimer's Disease (AD) K Kamisoglu, KK Muralidharan, I Nestorov JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S67-S67, 2018 | | 2018 |
Ioannis (Yannis) P. AndroulakisRutgers, The State University of New JerseyVerified email at soe.rutgers.edu
